Tumor Growth

Every compound in the sci-wiki that affects tumor growth; the ones you can source are floated to the front, then the reference-only entries. Tap any for the full entry, mechanism, and outlets.

0 sourced · 3 reference

←tumor growth3/3

Antineoplastic

Alisertib

An orally available, ATP-competitive small-molecule inhibitor of Aurora A kinase, an enzyme that regulates cell division. Developed by Takeda and later licensed to Puma Biotechnology, it was investigated across multiple cancer types including peripheral T-cell lymphoma, neuroendocrine prostate cancer, and acute myeloid leukemia.

reference

Antineoplastic

Erdafitinib

Erdafitinib (brand name Balversa) is an oral targeted cancer drug that blocks the fibroblast growth factor receptor (FGFR) family, a set of receptors that push cells to grow and divide. It is approved for advanced bladder (urothelial) cancer in people whose tumors carry FGFR2 or FGFR3 genetic changes. By shutting down that growth signal, it slows or shrinks tumors that lean on FGFR to keep expanding.

reference

Bone

Tyra-300

Tyra-300 is an investigational oral drug (from Tyra Biosciences) that selectively blocks FGFR3, one member of the fibroblast growth factor receptor family. It is being studied in two very different settings: bladder (urothelial) cancers driven by FGFR3 changes, and achondroplasia (a common form of dwarfism), where an overactive FGFR3 stunts bone growth. Its selling point is precision; it aims to hit FGFR3 while leaving the related FGFR1, FGFR2, and FGFR4 mostly alone. It is still in clinical trials and not an approved medicine.

reference